Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06721299 · ClinicalTrials.gov registry record · Phase 1
Clenbuterol to Target DUX4 in FSHD
A Phase 1 study of Muscular Dystrophy, Facioscapulohumeral, sponsored by Jeffrey Statland.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT06721299 is a Phase 1 study of Muscular Dystrophy, Facioscapulohumeral that is actively recruiting participants, run by Jeffrey Statland. The registered enrollment target is 30 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT06721299, a Phase 1 study of Muscular Dystrophy, Facioscapulohumeral, is actively recruiting participants, sponsored by Jeffrey Statland.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.
Conditions Studied
Interventions
- DRUG Clenbuterol
Study Locations (3)
Kansas
- University of Kansas Medical Center - Kansas City
New York
- University of Rochester Medical Center - Rochester
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-06-25 |
| Est. Completion | 2028-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06721299
The ClinicalTrials.gov registry entry for NCT06721299 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jeffrey Statland, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Muscular Dystrophy, Facioscapulohumeral appearing as the primary indexed condition, and to 1 intervention - of which Clenbuterol is the first listed.
NCT06721299 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Kansas, New York, Washington.
Frequently Asked Questions
What is clinical trial NCT06721299 about?
NCT06721299 is a clinical study titled "Clenbuterol to Target DUX4 in FSHD". The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.
What is the current status of trial NCT06721299?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-06-25. Estimated completion is 2028-07.
What conditions does trial NCT06721299 study?
This clinical trial studies the following conditions: Muscular Dystrophy, Facioscapulohumeral.
What interventions are being tested in trial NCT06721299?
The interventions under investigation include: Clenbuterol (DRUG).
Who is sponsoring clinical trial NCT06721299?
This trial is sponsored by Jeffrey Statland, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06721299 being conducted?
This trial has 3 study locations across Kansas, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscular Dystrophy, Facioscapulohumeral
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.